Department of Critical Care Medicine, Emergency General Hospital, Beijing, China.
Department of Emergency, Emergency General Hospital, Xibahe South Road 29, Chaoyang District, Beijing, 100028, People's Republic of China.
Eur J Med Res. 2023 Nov 21;28(1):536. doi: 10.1186/s40001-023-01403-0.
Several clinical trials have evaluated the efficacy and safety of baricitinib in COVID-19 patients. Recently, there have been reports on critical patients, which are different from previous research results. The meta-analysis was performed to investigate the effects of baricitinib in COVID-19, by pooling data from all clinically randomized controlled trials (RCTs) available to increase power to testify.
Studies were searched in PubMed, Embase, and Cochrane Library databases on January 31, 2023. We performed a meta-analysis to estimate the efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19. This study is registered with INPLASY, number 202310086.
A total of 3010 patients were included in our analyses. All included studies were randomized controlled trials or prospective study. There was no difference in 14-day mortality between the two groups [OR 0.23 (95% CI 0.03-1.84), I = 72%, P = 0.17]. In subgroup analyses we found that baricitinib did not seem to improve significantly in 24-day mortality critically ill patients [OR 0.60 (95% CI 0.35-1.02), I = 0%, P = 0.06]. Fortunately, baricitinib have led to faster recovery and shorter hospital stays for COVID-19 patients. There were no difference in infections and infestations, major adverse cardiovascular events, deep vein thrombosis and pulmonary embolism.
Baricitinib did not increase the incidence of adverse reactions. At the same time, we can find that it reduces the mortality of COVID-19 patients, not including the critically ill.
几项临床试验已经评估了巴瑞替尼在 COVID-19 患者中的疗效和安全性。最近，有关于重症患者的报告，与之前的研究结果不同。本荟萃分析旨在通过汇总所有可用的临床随机对照试验（RCT）的数据，以增加证明的效力，来调查巴瑞替尼在 COVID-19 中的作用。
我们于 2023 年 1 月 31 日在 PubMed、Embase 和 Cochrane Library 数据库中检索研究。我们进行了一项荟萃分析，以评估巴瑞替尼治疗住院 COVID-19 成人的疗效和安全性。本研究在 INPLASY 注册，编号为 202310086。
我们的分析共纳入了 3010 名患者。所有纳入的研究均为随机对照试验或前瞻性研究。两组之间 14 天死亡率无差异[OR 0.23（95%CI 0.03-1.84），I=72%，P=0.17]。在亚组分析中，我们发现巴瑞替尼似乎不能显著改善重症患者 24 天死亡率[OR 0.60（95%CI 0.35-1.02），I=0%，P=0.06]。幸运的是，巴瑞替尼使 COVID-19 患者更快康复并缩短住院时间。两组之间在感染和寄生虫感染、主要不良心血管事件、深静脉血栓和肺栓塞方面无差异。
巴瑞替尼并未增加不良反应发生率。同时，我们可以发现它降低了 COVID-19 患者的死亡率，不包括重症患者。
